AOBiome develops a novel class of therapeutics based on ammonia-oxidizing bacteria (AOB) that consume ammonia and produce nitrite and nitric oxide, signaling molecules that regulate inflammation and vasodilation. The company sells consumer biome-friendly products under the Mother Dirt brand while advancing clinical-stage drug candidates. AOBiome is pursuing host-regulated drug approaches and positions its AOB platform as a potential first FDA‑approved therapy of this type. The company has launched a Phase 2 clinical trial for hypertension and initiated a Phase 2B acne vulgaris trial. AOBiome frames its work within a “Germ Theory of Health,” aiming to repopulate keystone commensal bacteria lost through modern hygiene. It operates from Boston and San Francisco and was founded in 2013.

Total raised

$30M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2017